Know Cancer

or
forgot password

Radioactive Holmium Microspheres for the Treatment of Patients With Unresectable Liver Metastases; a Single Center, Interventional, Non-randomized, Phase II (HEPAR II) Trial


Phase 2
18 Years
N/A
Open (Enrolling)
Both
Liver Neoplasms

Thank you

Trial Information

Radioactive Holmium Microspheres for the Treatment of Patients With Unresectable Liver Metastases; a Single Center, Interventional, Non-randomized, Phase II (HEPAR II) Trial

Inclusion Criteria


List of inclusion criteria:

- 1. Patients must have given written informed consent.

- 2. Female or male aged 18 years and over.

- 3. Diagnosis of metastatic malignancy to the liver and no detectable malignant
disease outside the liver or diagnosis of metastatic malignancy to the liver with
limited disease outside the liver (i.e. liver-dominant disease) defined as the sum of
the diameters of all metastases in the liver to be more than 200% of the sum of the
diameters of all soft tissue lesions outside the liver.

- 4. Patient is not amenable for standard therapies (other than radioembolisation) or
patient refuses standard therapies for reasons of toxicity

- 5. Life expectancy of 12 weeks or longer.

- 6. World Health Organisation (WHO) Performance status 0-2 (see Appendix III).

List of exclusion criteria:

1. Brain metastases or spinal cord compression, unless irradiated at least 4 weeks prior
to the date of the experimental treatment and stable without steroid treatment for at
least 1 week.

2. Radiation therapy within the last 4 weeks before the start of study therapy.

3. The last dose of prior chemotherapy has been received less than 4 weeks prior the
start of study therapy.

4. Major surgery within 4 weeks, or incompletely healed surgical incision before
starting study therapy.

5. Any unresolved toxicity greater than National Cancer Institute (NCI), Common
Terminology Criteria for Adverse Events (CTCAE version 4.0, see Appendix II) grade 2
from previous anti-cancer therapy.

6. Serum bilirubin > 1.5 x Upper Limit of Normal (ULN).

7. Glomerular filtration rate <35 ml/min, determined according to the Modification of
Diet in Renal Disease formula.

8. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or alkaline
phosphatase (ALP) > 5 x ULN.

9. Leukocytes < 4.0 109/l and/or platelet count < 150 109/l.

10. Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC)
syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 within
3 months before entry, or presence of cardiac disease that in the opinion of the
Investigator increases the risk of ventricular arrhythmia.

11. Pregnancy or breast feeding (women of child-bearing potential).

12. Patients suffering from diseases with a increased chance of liver toxicity, such as
primary biliary cirrhosis or xeroderma pigmentosum.

13. Patients suffering from psychic disorders that make a comprehensive judgement
impossible, such as psychosis, hallucinations and/or depression.

14. Patients who are declared incompetent.

15. Previous enrolment in the present study or previous treatment with radioembolisation.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Target lesions tumour response

Outcome Description:

After the administration of the Ho-166 microspheres the size of the target lesions in the liver will be determined using RECIST 1.1 criteria using CT scan

Outcome Time Frame:

3 month after treatment

Safety Issue:

No

Principal Investigator

Bernard Zonnenberg, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UMCU Utrecht Netherlands

Authority:

Netherlands: Dutch Health Care Inspectorate

Study ID:

UMCU-11-538

NCT ID:

NCT01612325

Start Date:

May 2012

Completion Date:

December 2013

Related Keywords:

  • Liver Neoplasms
  • liver tumors
  • Neoplasms
  • Liver Neoplasms
  • Neoplasm Metastasis

Name

Location